My site

SHANGHAI - Thursday, 27. February 2025

AI-NR and AI-SR families deliver high efficiency, scalability, and excellent picture quality across multiple applications

(BUSINESS WIRE) -- VeriSilicon (688521.SH) today announced the launch of its latest AI-based AI-NR and AI-SR series of image processing IPs, including the AINR1000 and AINR2000 for intelligent noise reduction, and the AISR1000 and AISR2000 for advanced super resolution. These series IPs provide cost-effective, highly efficient, and PPA (performance, power efficiency, area) optimized implementations with high flexibility and scalability, making them ideal for a wide range of applications, including automotive, surveillance, cloud gaming, consumer electronics, and more.

VeriSilicon’s AI-NR and AI-SR series IPs leverage the company’s proprietary AI pixel processing algorithms to deliver advanced image processing capabilities. The AINR1000 and AINR2000 IPs effectively suppress noise while pres ... Read more »

MEUDON, France - 
Cubic, a leading global provider of software-defined vehicle (SDV) solutions integrates Thales's eSIM technology to address the rising need for smart and efficient connectivity that matches the latest GSMA standards.
Thales, a worldwide eSIM management platform leader, has driven reliable successful deployments in high-volume device markets, making it ideally suited to support Cubic.
 

(BUSINESS WIRE) -- Thales, a global leader in advanced technologies, and Cubic, a leading global provider of software-defined vehicle (SDV) solutions, have announced a collaboration to drive innovation and simplify connectivity management. Leveraging Thales’s eSIM management platform, Cubic will enhance its eSIM solution capabilities to align with the latest GSMA standards, ensuring seamless global connectivity across industries such as automotive, transportation, and agriculture.

With the adoption of the GSMA SGP.32* standard for ... Read more »

NEW YORK - Thursday, 27. February 2025 AETOSWire 

SLB subsidiary commences offer to exchange certain outstanding existing series of notes for up to $2.0 billion aggregate principal amount of new series of notes

(BUSINESS WIRE) -- Schlumberger Limited (“SLB”) (NYSE: SLB) today announced that Schlumberger Holdings Corporation, an indirect wholly owned subsidiary of SLB (“SHC”), has commenced offers to exchange certain series of notes listed below (the “Existing SISA Notes”), issued by Schlumberger Investment S.A. (“SISA”), for up to $2,000,000,000 aggregate principal amount (such amount, as it may be amended, the “Maximum Exchange Amount”) of new notes listed below (the “New SHC Notes”), to be issued by SHC, and to be fully and unconditionally guaranteed on a senior unsecured basis by SLB. The offers to exchange each series of Existing SISA Notes for the corresponding series of New SHC Notes a ... Read more »

WESTFORD, Mass. - Thursday, 27. February 2025

(BUSINESS WIRE)--Cynosure Lutronic, a global leader in the energy-based devices market, has entered into a multi- country distribution agreement with Amico Aesthetics, a leader in providing world-class medical devices to the Middle East.

Effective January 1, 2025, Amico Aesthetics has become the sole authorized distributor of the whole Cynosure Lutronic portfolio across its entire network in the Middle East including UAE, KSA, Kuwait, Qatar, Jordan, Iraq, Egypt, Bahrain, Oman and Lebanon. This strategic relationship further strengthens both companies’ presence and commitment to customer excellence in the region's energy-based device industry.

A Leading-Edge Alliance

This alliance unites Cynosure Lutronic’s innovative technologies with Amico Aesthetics’ robust distribution network and localized expertise, creating a powerful synergy aimed at delivering unparalleled value to aesthetic pr ... Read more »

 -- Trial Designed to Demonstrate Efficacy and Safety of Every 3- and Every 6-Month Administration in a 6-Month Treatment Period --

(BUSINESS WIRE)--Astria Therapeutics, Inc. (Nasdaq:ATXS), a biopharmaceutical company focused on developing life-changing therapies for allergic and immunologic diseases, today announced the initiation of the ALPHA-ORBIT Phase 3 clinical trial of navenibart in people living with hereditary angioedema (HAE). Navenibart has the potential to provide rapid and sustained HAE attack prevention with a very low treatment burden and administration every 3 months (Q3M) and every 6 months (Q6M).

“We believe that navenibart will deliver strong efficacy, low treatment burden, and favorable safety and tolerability and we are thrilled to have initiated our Phase 3 ALPHA-ORBIT trial to support that vision,” said Christopher Morabito, M.D., Chief Medical Officer at Astria Therapeutics. “The Phase 3 pro ... Read more »